Alan H Shih
Overview
Explore the profile of Alan H Shih including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
2790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Balev M, Zibara V, Van Hyfte G, Feld J, Kremyanskaya M, Becker M, et al.
Am J Hematol
. 2024 Jul;
99(10):2026-2028.
PMID: 38970273
Multivariable analysis for overall survival and relapse-free survival demonstrating lack of significant for D14 BM status.
2.
Waarts M, Mowla S, Boileau M, Martinez Benitez A, Sango J, Bagish M, et al.
Cancer Discov
. 2024 May;
14(10):1860-1878.
PMID: 38819218
Clonal hematopoiesis (CH) is a common premalignant state in the blood and confers an increased risk of blood cancers and all-cause mortality. Identification of therapeutic targets in CH has been...
3.
Handa S, Farina K, Becker M, Kelly B, Yu A, Feld J, et al.
JCO Precis Oncol
. 2024 Jan;
8:e2300234.
PMID: 38295318
We report the first case of pacritinib-withdrawal syndrome with in vitro elucidation of underlying mechanisms.
4.
Marcellino B, Yang X, Umit Kaniskan H, Brady C, Chen H, Chen K, et al.
Leukemia
. 2023 Jun;
37(8):1764-1765.
PMID: 37391487
No abstract available.
5.
Marcellino B, Yang X, Umit Kaniskan H, Brady C, Chen H, Chen K, et al.
Leukemia
. 2022 Oct;
37(2):370-378.
PMID: 36309559
In acute myeloid leukemia (AML), p53 tumor suppressor activity can be reduced due to enhanced expression of MDM2 which promotes the degradation of p53. In TP53 wild-type malignancies, therapy with...
6.
Feld J, Tremblay D, Dougherty M, Czaplinska T, Sanchez G, Brady C, et al.
Hemasphere
. 2021 Mar;
5(4):e549.
PMID: 33718803
Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have relapsed/refractory (R/R)...
7.
Chen K, Shih A
Hematol Oncol Clin North Am
. 2021 Mar;
35(2):253-265.
PMID: 33641867
Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are bone marrow disorders that result in the overproduction of mature clonal myeloid elements. Identification of recurrent genetic mutations...
8.
Tremblay D, Feld J, Dougherty M, Czaplinska T, Sanchez G, Kremyanskaya M, et al.
Leuk Res
. 2020 Oct;
98:106456.
PMID: 33002673
No abstract available.
9.
Li S, Chen X, Wang J, Meydan C, Glass J, Shih A, et al.
Cancer Discov
. 2020 Sep;
10(12):1934-1949.
PMID: 32938585
Epigenetic allele diversity is linked to inferior prognosis in acute myeloid leukemia (AML). However, the source of epiallele heterogeneity in AML is unknown. Herein we analyzed epiallele diversity in a...
10.
Duy C, Teater M, Garrett-Bakelman F, Lee T, Meydan C, Glass J, et al.
Cancer Discov
. 2019 May;
9(7):872-889.
PMID: 31076479
Disruption of epigenetic regulation is a hallmark of acute myeloid leukemia (AML), but epigenetic therapy is complicated by the complexity of the epigenome. Herein, we developed a long-term primary AML...